Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 7/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 7/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 7/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.38 |
| ▸ | DRD4 | P21917 | 5/20 | 0.38 |
| ▸ | DRD3 | P35462 | 5/20 | 0.38 |
| ▸ | HEXA | P06865 | 1/20 | 0.36 |
| ▸ | HEXB | P07686 | 1/20 | 0.36 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587653 | 0.82 | POLB (0.38) | MAP2K1POLBCHRM1CHRM2CHRM4 | |
| SCHEMBL3602292 | 0.76 | LOXL2 (0.46) | POLBCHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3588021 | 0.76 | SRD5A1 (0.45) | MAP2K1DRD2ATAD2HTR1A | |
| SCHEMBL14277003 | 0.74 | POLB (0.61) | POLBCHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL2674065 | 0.73 | HRH1 (0.43) | POLBCHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL282756 | 0.70 | KMT2A (0.39) | POLBCHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3605572 | 0.70 | ATAD2 (0.52) | POLBCHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL9689691 | 0.70 | MAPT (0.41) | MAP2K1POLBCHRM1CHRM2CHRM4 | |
| SCHEMBL3599801 | 0.70 | ATAD2 (0.68) | POLBCHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL8126459 | 0.69 | MAP2K1 (0.40) | MAP2K1ATAD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | MAP2K1 1707/4885POLB 1341/4885CHRM1 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.